Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
GlaxoSmithKline Eesti OU, commonly referred to as GSK Estonia, is a prominent player in the pharmaceutical and healthcare industry, headquartered in Estonia (EE). Established in the early 2000s, GSK has made significant strides in the region, focusing on research and development, manufacturing, and marketing of innovative medicines and vaccines.
With a strong presence across the Baltic states, GSK Estonia is dedicated to improving health outcomes through its core offerings, which include prescription pharmaceuticals, consumer healthcare products, and vaccines. The company is renowned for its commitment to quality and innovation, positioning itself as a leader in the market. GSK's notable achievements include advancements in respiratory and immunology treatments, underscoring its role as a trusted partner in healthcare.
+73 vs industry average
GlaxoSmithKline Eesti OU’s score of 100 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Membership Services has below-average carbon intensity
The Membership Services industry has reduced its overall emissions by 37% since 2018
No reported emissions data is available for GlaxoSmithKline Eesti OU yet.
GlaxoSmithKline Eesti OU, headquartered in Estonia (EE), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of GSK plc, which means that any climate commitments or emissions data may be cascaded from its parent organisation.
GSK plc has established various climate initiatives, including Science Based Targets Initiative (SBTi) commitments, CDP reporting, and participation in the RE100 initiative, all of which are relevant to GlaxoSmithKline Eesti OU's climate strategy. However, specific reduction targets or achievements for GlaxoSmithKline Eesti OU have not been disclosed.
As a subsidiary, GlaxoSmithKline Eesti OU aligns with the broader sustainability goals set by GSK plc, which focuses on reducing carbon emissions across its operations. The absence of specific emissions data highlights the need for further transparency and reporting at the subsidiary level to fully understand its environmental impact and commitments.
No climate goals have been disclosed for GlaxoSmithKline Eesti OU yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for GlaxoSmithKline Eesti OU yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more